From diagnosis to treatment selection and therapy monitoring, NGS is becoming an inevitable pillar of modern healthcare — and an expanding share of healthcare spending.

As volumes increase, the financial and governance consequences of diagnostic errors and repeat testing become systemic. Ensuring accuracy is no longer optional; it is foundational to sustainable healthcare systems.

DName‑iT introduces molecular identity assurance that strengthens accountability across the entire testing pathway.

​

For Public Healthcare Systems & Governments

• Reduce Waste in Publicly Funded Diagnostics
Minimise avoidable repeat testing caused by sample misidentification or contamination.

• Strengthen Confidence in Population‑Scale Screening
Enable reliable expansion of national genomics and early detection programs.

• Improve Traceability & Auditability
Provide documented identity verification across distributed laboratory networks.
• Enhance accountability in National Testing Initiatives.
Support transparent governance in publicly financed diagnostic services.

​

For Insurance Companies & Private Payers

• Lower Downstream Costs
Reduce unnecessary re‑tests, corrective procedures, and diagnostic inefficiencies.

• Support Evidence‑Based Reimbursement
Strengthen justification for claims through embedded quality assurance and documented traceability.

• Reduce Liability & Claims Risk
Mitigate exposure linked to sample misidentification and reporting errors.

​

By reducing repeat testing, strengthening documentation integrity, and embedding automated identity verification, DName‑iT supports both clinical reliability and long‑term financial sustainability in modern healthcare systems.

In a landscape where genomics is no longer optional, infrastructure‑level quality assurance becomes essential.

​

​